Citations

Clear

6274 citation(s) found for "To, Andrew".

Risk of Early Versus Later Rebleeding From Dural Arteriovenous Fistulas With Cortical Venous Drainage
Durnford, Andrew , Akarca, Danyal , Culliford, David , Millar, John S. , Guniganti, Ridhima , Giordan, Enrico , Brinjikji, Waleed , Chen, Ching‐Jen , Abecassis, Isaac Josh , Levitt, Michael R. , Polifka, Adam , Derdeyn, Colin P. , Kwasnicki, Amanda , Alaraj, Ali , Potgieser, Adriaan R. E., Tada, Yoshiteru , Abla, Adib A. , Satomi, Junichiro, Starke, Robert M., Dijk, J. Marc C. van , Amin‐Hanjani, Sepideh , Hayakawa, M. , Gross, Bradley A. , Kim, Louis J. , Sheehan, Jason P. , Kansagra, Akash P. , Lai, Rosalind, Zipfel, Gregory J. , Bulters, Diederik , Piccirillo, Jay F. , Vine, Roanna , Cloft, Harry J. , Kallmes, David F. , Pollock, Bruce E. , Link, Michael J. , Patibandla, Mohana Rao, Ding, Dale , Buell, Thomas J. , Paisan, Gabriella, Meyer, R. Michael, Kelly, Cory , Duffill, Jonathan, Ditchfield, Adam, Macdonald, Jason, Laurent, Dimitri , Lockerman, Ashley, Lunsford, L. Dade , Jankowitz, Brian T. , Guerrero, Waldo R. , McGruder, Allen, Charbel, Fady T. , Aletich, Victor , Rose‐Finnell, Linda, Peterson, Eric C. , Yavagal, Dileep R. , Sur, Samir , Kanematsu, Yasuhisa , Kinouchi, T. , Korai, Masaaki , Yamaguchi, Izumi , Yamamoto, Yuki , Winkler, Ethan A. , Lawton, Michael T. , Rutkowski, Martin J. , Sultan, M. Ali Aziz, Patel, Nirav , Frerichs, Kai U., Levitt, Michael R , Polifka, Adam J , Samaniego, Edgar A , Alaraj, Ali , Tada, Yoshiteru , Phelps, Ryan , Abla, Adib , van DijK, J Marc C , Amin-Hanjani, Sepideh , Gross, Bradley , Fox, W Christopher , Kim, Louis J. , Sheehan, Jason , Lanzino, Giuseppe , Kansagra, Akash P , Du, Rose , Lai, Rosalind , Zipfel, Gregory J , Bulters, Diederik O , Ding, Dale , Chen, Ching-Jen , Derdeyn, Colin P , Abecassis, Isaac Josh , Millar, John, Chen, Stephanie , Lanzino, Giuseppe , Raman, Hari S. , Lipsey, Kim L. , Hoh, Brian L. , Smith, Jessica , Ortega-Gutierrez, Santiago , Hasan, David , Roa, Jorge A. , Rossen, James D. , Yamamoto, Nobuaki

Mayo Clinic

Stroke | April 14, 2022 | Volume: 53 | Issue: 7 | Pages: 2340-2345

10.1161/strokeaha.121.036450 | PMID 35420453 Get It

Background: Cranial dural arteriovenous fistulas with cortical venous drainage are rare lesions that can present with hemorrhage. A high rate of rebleeding in the early period following hemorrhage has been reported, but published long-term rates are much lower. No study has examined how risk of rebleeding changes over time. Our objective was to quantify the relative incidence of rebleeding in the early and later periods following hemorrhage. Methods: Patients with dural arteriovenous fistula and cortical venous drainage presenting with hemorrhage were identified from the multinational CONDOR (Consortium for Dural Fistula Outcomes Research) database. Natural history follow-up was defined as time from hemorrhage to first treatment, rebleed, or last follow-up. Rebleeding in the first 2 weeks and first year were compared using incidence rate ratio and difference. Results: Of 1077 patients, 250 met the inclusion criteria and had 95 cumulative person-years natural history follow-up. The overall annualized rebleed rate was 7.3% (95% CI, 3.2–14.5). The incidence rate of rebleeding in the first 2 weeks was 0.0011 per person-day; an early rebleed risk of 1.6% in the first 14 days (95% CI, 0.3–5.1). For the remainder of the first year, the incidence rate was 0.00015 per person-day; a rebleed rate of 5.3% (CI, 1.7–12.4) over 1 year. The incidence rate ratio was 7.3 (95% CI, 1.4–37.7; P , 0.026). Conclusions: The risk of rebleeding of a dural arteriovenous fistula with cortical venous drainage presenting with hemorrhage is increased in the first 2 weeks justifying early treatment. However, the magnitude of this increase may be considerably lower than previously thought. Treatment within 5 days was associated with a low rate of rebleeding and appears an appropriate timeframe.
CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter Analysis
Wohlmuth, Christoph , Djedovic, Vladimir, Kjær, Susanne K. , DeFazio, Anna , Johnatty, Sharon E. , Webb, Penelope M. , Lambrechts, Diether , Schildkraut, Joellen M. , Thomsen, Liv Cecilie Vestrheim , Bjørge, Line , Høgdall, Estrid , Høgdall, Claus , Goode, Ellen L. , Matsuo, Keitaro , Karlan, Beth Y. , Lester, Jenny, Goodman, Marc T. , Thompson, Pamela J., Riggan, Marjorie J. , Lajkosz, Katherine , Tone, Alicia , May, Taymaa, Lambrechts, Diether , Fazio, Anna de , Webb, Penelope M , Thomsen, Liv Cecilie Vestrheim , Bjorge, Line , Høgdall, Estrid , Høgdall, Claus K , Matsuo, Keitaro , Karlan, Beth Y , Tone, Alicia , Lambrechts, Diether , Kjaer, Susanne K , Lambrechts, Diether , Goodman, Marc T , Jensen, Allan , Glasspool, Rosalind , Roxburgh, Patricia , Modugno, Francesmary , Berchuck, Andrew , Winham, Stacey J. , Pejovic, Tanja B.

Mayo Clinic

Cancers | April 13, 2022 | Volume: 14 | Issue: 8 | Pages: 1954

10.3390/cancers14081954 | PMID 35454861 Get It

Objective: Studies on low-grade serous ovarian cancer (LGSC) are limited by a low number of cases. The aim of this study was to define the prognostic significance of age, stage, and CA-125 levels on survival in a multi-institutional cohort of women with pathologically confirmed LGSC. Methods: Women with LGSC were identified from the collaborative Ovarian Cancer Association Consortium (OCAC). Cases of newly diagnosed primary LGSC were included if peri-operative CA-125 levels were available. Age at diagnosis, FIGO stage, pre- and post-treatment CA-125 levels, residual disease, adjuvant chemotherapy, disease recurrence, and vital status were collected by the participating institutions. Progression-free (PFS) and overall survival (OS) were calculated. Multivariable (MVA) Cox proportional hazard models were used and hazard ratios (HR) calculated. Results: A total of 176 women with LGSC were included in this study; 82% had stage III/IV disease. The median PFS was 2.3 years and the median OS was 6.4 years. Age at diagnosis was not significantly associated with worse PFS (p = 0.23) or OS (p = 0.3) (HR per year: 0.99; 95%CI, 0.96–1.01 and 0.98; 95%CI 0.95–1.01). FIGO stage III/IV was independently associated with PFS (HR 4.26, 95%CI 1.43–12.73) and OS (HR 1.69, 95%CI 0.56–5.05). Elevated CA-125 (≥35 U/mL) at diagnosis was not significantly associated with worse PFS (p = 0.87) or OS (p = 0.78) in MVA. Elevated CA-125 (≥35 U/mL) after completion of primary treatment was independently associated with worse PFS (HR 2.81, 95%CI 1.36–5.81) and OS (HR 6.62, 95%CI 2.45–17.92). In the MVA, residual disease was independently associated with PFS (0.022), but not OS (0.85). Conclusion: Advanced LGSC was associated with poor long-term prognosis. FIGO stage and abnormal post-treatment CA-125 level are key prognostic factors inversely associated with PFS and OS. Highlights: 1. Through a multi-center collaborative effort, data from 176 women with low-grade serous ovarian cancer were analyzed. 2. Although low-grade serous ovarian cancer is often considered indolent, the progression-free and overall survival are poor. 3. Elevated post-treatment CA-125 levels are independently associated with poor survival.
Turning a Page in the Yellow Journal: Figure Legends and Gender-Inclusive Patient Descriptors
Doo, Florence X., Zavaletta, Vaz, Carroll, Evelyn F., Ellis, Keri L., Rosenkrantz, Andrew B., Doo, Florence Xini , Zavaletta, Vaz, Carroll, Evelyn F., Ellis, Keri L., Rosenkrantz, Andrew B.

Mayo Clinic

American Journal of Roentgenology | April 13, 2022 | Volume: 219 | Issue: 1 | Pages: 1-2

10.2214/ajr.22.27536 | PMID 35417186 Get It

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
Prawira, Amy , Antonia, Scott , Rahma, Osama E. , Cohen, Roger B. , Lou, Yanyan , Hauke, Ralph J. , Zandberg, Dan P. , Kalebasty, Arash Rezazadeh, Atkinson, Victoria , Adjei, Alex A. , Seetharam, ­Mahesh , Birnbaum, Ariel E., Weickhardt, Andrew , Ganju, Vinod , Cavallo, Rosetta, Zhang, Xiaoyu , Kaul, Sanjeev, Baughman, Jan, Bonvini, Ezio , Moore, Paul A. , Goldberg, S., Arnaldez, Fernanda I. , Aggarwal, Charu , Tolcher, Anthony W. , Vogelzang, Nicholas J. , Joshua, Anthony M. , Peng, Linda , Kaul, Sanjeev, Ferris, Robert L. , Lakhani, Nehal J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | April 12, 2022 | Volume: 10 | Issue: 4 | Pages: e004424

10.1136/jitc-2021-004424 | PMID 35414591 Get It

Background Availability of checkpoint inhibitors has created a paradigm shift in the management of patients with solid tumors. Despite this, most patients do not respond to immunotherapy, and there is considerable interest in developing combination therapies to improve response rates and outcomes. B7-H3 (CD276) is a member of the B7 family of cell surface molecules and provides an alternative immune checkpoint molecule to therapeutically target alone or in combination with programmed cell death-1 (PD-1)–targeted therapies. Enoblituzumab, an investigational anti-B7-H3 humanized monoclonal antibody, incorporates an immunoglobulin G1 fragment crystallizable (Fc) domain that enhances Fcγ receptor-mediated antibody-dependent cellular cytotoxicity. Coordinated engagement of innate and adaptive immunity by targeting distinct members of the B7 family (B7-H3 and PD-1) is hypothesized to provide greater antitumor activity than either agent alone. Methods In this phase I/II study, patients received intravenous enoblituzumab (3–15 mg/kg) weekly plus intravenous pembrolizumab (2 mg/kg) every 3 weeks during dose-escalation and cohort expansion. Expansion cohorts included non–small cell lung cancer (NSCLC; checkpoint inhibitor [CPI]–naïve and post-CPI, programmed death-ligand 1 [PD-L1] <1%), head and neck squamous cell carcinoma (HNSCC; CPI-naïve), urothelial cancer (post-CPI), and melanoma (post-CPI). Disease was assessed using Response Evaluation Criteria in Solid Tumors version 1.1 after 6 weeks and every 9 weeks thereafter. Safety and pharmacokinetic data were provided for all enrolled patients; efficacy data focused on HNSCC and NSCLC cohorts. Results Overall, 133 patients were enrolled and received ≥1 dose of study treatment. The maximum tolerated dose of enoblituzumab with pembrolizumab at 2 mg/kg was not reached. Intravenous enoblituzumab (15 mg/kg) every 3 weeks plus pembrolizumab (2 mg/kg) every 3 weeks was recommended for phase II evaluation. Treatment-related adverse events occurred in 116 patients (87.2%) and were grade ≥3 in 28.6%. One treatment-related death occurred (pneumonitis). Objective responses occurred in 6 of 18 (33.3% [95% CI 13.3 to 59.0]) patients with CPI-naïve HNSCC and in 5 of 14 (35.7% [95% CI 12.8 to 64.9]) patients with CPI-naïve NSCLC. Conclusions Checkpoint targeting with enoblituzumab and pembrolizumab demonstrated acceptable safety and antitumor activity in patients with CPI-naïve HNSCC and NSCLC. Trial registration number NCT02475213.
Comparison of Recent Practice Guidelines for the Management of Patients With Asymptomatic Carotid Stenosis
Paraskevas, Kosmas I. , Mikhailidis, Dimitri P. , Ascher, Enrico, Baradaran, Hediyeh , Bokkers, Reinoud P.H. , Cambria, Richard P., Comerota, Anthony J. , Dardik, Alan , Davies, Alun H. , Faggioli, Gianluca , Fraedrich, Gustav , Geroulakos, George , Gloviczki, Péter , Golledge, Jonathan , Gupta, Ajay , Ježovnik, Mateja K. , Kakkos, Stavros K. , Katsiki, Niki , Knoflach, Michael , Kooi, M. Eline , Lavenson, George S., Loftus, Ian , Millon, Antoine , Poredoš, Pavel , Proczka, Robert M. , Riles, Thomas S., Saba, Luca , Schlachetzki, Felix , Silvestrini, Mauro , Spinelli, Francesco , Stilo, Francesco , Suri, Jasjit S. , Zeebregts, Clark J. , Jezovnik, Mateja K , Katsiki, Niki , Pini, Rodolfo , Poredos, Pavel , Svetlikov, Alexei V , Paraskevas, Kosmas I , Davies, Alun H , Kooi, Marianne Eline , Antignani, Pier Luigi , Eckstein, Hans‐Henning , Fernandes, José Fernandes e , Lanza, Gaetano A , Liapis, Christos D. , Mansilha, Armando , Nicolaides, Andrew , Ricco, Jean‐Baptiste , Ringleb, Peter Arthur , Rundek, Tatjana , Saba, Luca , Sultan, Sherif A. H. , Suri, Jasjit S. , Chaturvedi, Seemant , Gloviczki, Péter

Mayo Clinic

Angiology | April 12, 2022 | Volume: 73 | Issue: 10 | Pages: 903-910

10.1177/00033197221081914 | PMID 35412377 Get It

Despite the publication of several national/international guidelines, the optimal management of patients with asymptomatic carotid stenosis (AsxCS) remains controversial. This article compares 3 recently released guidelines (the 2020 German–Austrian, the 2021 European Stroke Organization [ESO], and the 2021 Society for Vascular Surgery [SVS] guidelines) vs the 2017 European Society for Vascular Surgery (ESVS) guidelines regarding the optimal management of AsxCS patients. The 2017 ESVS guidelines defined specific imaging/clinical parameters that may identify patient subgroups at high future stroke risk and recommended that carotid endarterectomy (CEA) should or carotid artery stenting (CAS) may be considered for these individuals. The 2020 German–Austrian guidelines provided similar recommendations with the 2017 ESVS Guidelines. The 2021 ESO Guidelines also recommended CEA for AsxCS patients at high risk for stroke on best medical treatment (BMT), but recommended against routine use of CAS in these patients. Finally, the SVS guidelines provided a strong recommendation for CEA+BMT vs BMT alone for low-surgical risk patients with >70% AsxCS. Thus, the ESVS, German–Austrian, and ESO guidelines concurred that all AsxCS patients should receive risk factor modification and BMT, but CEA should or CAS may also be considered for certain AsxCS patient subgroups at high risk for future ipsilateral ischemic stroke.
Perioperative outcomes of patients with restless legs syndrome: a single-center retrospective review
Gali, Bhargavi , Silber, Michael H. , Hanson, Andrew C. , Portner, Erica , Gay, Peter C. , Gay, Peter

Mayo Clinic

Journal of Clinical Sleep Medicine | April 11, 2022 | Volume: 18 | Issue: 7 | Pages: 1841-1846

10.5664/jcsm.10000 | PMID 35393939 Get It

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
Gounder, Mrinal M. , Razak, Albiruni Abdul , Somaiah, Neeta , Chawla, Sant P. , Martín‐Broto, Javier , Schuetze, Scott M. , Vincenzi, Bruno , Wagner, Andrew J. , Chmielowski, Bartosz , Jones, Robin L. , Riedel, Richard F. , Stacchiotti, Silvia , Ganjoo, Kristen N. , Cesne, Axel Le , Italiano, Antoîne , Ryan, Christopher W. , Mulcahy, Mary F. , Forscher, Charles, Okuno, Scott H. , Hartner, Lee , Philip, Tony , Alcindor, Thierry , Reichardt, Peter , Chevreau, Christine , Morales, Claudia Maria Valverde, Chen, James L. , Deshpande, Hari A. , Nicholas, Garth , Gröschel, Stefan , Hatcher, Helen, Duffaud, Florence , Beveridge, Roberto Díaz, Meyer, Christian F. , Götze, Katharina S. , Mazzeo, F , Yakobson, Alexander, Zick, Aviad , Lee, Alexander T.J. , Estival, Anna , Napolitano, Andrea , Dickson, Mark A. , Michel, Dayana , Meng, Changting , Ben‐Shahar, Osnat , Chang, Hua, Landesman, Yosef , Shah, Jatin J., Shacham, Sharon, Kauffman, Michael , Attia, Steven , Schuetze, Scott M , Vincenzi, Bruno , Wagner, Andrew J , Chmielowski, Bartosz , Jones, Robin L , Riedel, Richard F , Loggers, Elizabeth T , Le Cesne, Axel , Italiano, Antoine , Garcia Del Muro, Xavier , Mulcahy, Mary F , Penel, Nicolas , Okuno, Scott , Elias, Anthony D , Hartner, Lee , Philip, Tony , Alcindor, Thierry , Lapeire, Lore , Blay, Jean-Yves , Chen, James L , Davis, Elizabeth J , Hatcher, Helen , Meyer, Christian , von Mehren, Margaret , Van Tine, Brian A , Götze, Katharina , Mazzeo, Filomena , Zick, Aviad , Lee, Alexander , Gonzalez, Anna Estival , Napolitano, Andrea , Michel, Dayana , Meng, Changting , Ben-Shahar, Osnat , Van Domelen, Dane R , Grignani, Giovanni , Burgess, Melissa , Piperno‐Neumann, Sophie , Elias, Anthony , Kasper, Bernd , Blay, Jean‐Yves , Schwartz, Gary K. , Davis, Elizabeth J. , Casado, Antonio , Badalamenti, Giuseppe , Eriksson, Mikael , Mehren, Margaret von , Tine, Brian A. Van , Li, Lingling , Liu, Jianjun , Walker, Christopher James

Mayo Clinic

Journal of Clinical Oncology | April 8, 2022 | Volume: 40 | Issue: 22 | Pages: 2479-2490

10.1200/jco.21.01829 | PMID 35394800 Get It

PURPOSE Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents. METHODS SEAL was a phase II-III, multicenter, randomized, double-blind, placebo-controlled study. Patients age 12 years or older with advanced DD-LPS who had received two-five lines of therapy were randomly assigned (2:1) to selinexor (60 mg) or placebo twice weekly in 6-week cycles (crossover permitted). The primary end point was progression-free survival (PFS). Patients who received at least one dose of study treatment were included for safety analysis (ClinicalTrials.gov identifier: NCT02606461 ). RESULTS Two hundred eighty-five patients were enrolled (selinexor, n = 188; placebo, n = 97). PFS was significantly longer with selinexor versus placebo: hazard ratio (HR) 0.70 (95% CI, 0.52 to 0.95; one-sided P = .011; medians 2.8 v 2.1 months), as was time to next treatment: HR 0.50 (95% CI, 0.37 to 0.66; one-sided P < .0001; medians 5.8 v 3.2 months). With crossover, no difference was observed in overall survival. The most common treatment-emergent adverse events of any grade versus grade 3 or 4 with selinexor were nausea (151 [80.7%] v 11 [5.9]), decreased appetite (113 [60.4%] v 14 [7.5%]), and fatigue (96 [51.3%] v 12 [6.4%]). Four (2.1%) and three (3.1%) patients died in the selinexor and placebo arms, respectively. Exploratory RNA sequencing analysis identified that the absence of CALB1 expression was associated with longer PFS with selinexor compared with placebo (median 6.9 v 2.2 months; HR, 0.19; P = .001). CONCLUSION Patients with advanced, refractory DD-LPS showed improved PFS and time to next treatment with selinexor compared with placebo. Supportive care and dose reductions mitigated side effects of selinexor. Prospective validation of CALB1 expression as a predictive biomarker for selinexor in DD-LPS is warranted.
Immunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR‐T
Kase, Adam M. , Kharfan‐Dabaja, Mohamed A. , Donaldson, Andrew , Elliott, Jamie, Sher, Taimur , Elliott, Jamie

Mayo Clinic

Clinical Case Reports | April 8, 2022 | Volume: 10 | Issue: 4 | Pages: No page available

10.1002/ccr3.5572 | PMID 35425600 Get It

AbstractPatients with relapsed follicular lymphoma who do not respond to CAR‐T have a poor outcome. We present a case of refractory follicular lymphoma who relapsed after two CAR‐T infusions and achieved a complete remission after treatment with obinutuzumab and lenalidomide. This represents a promising treatment option in the post‐CAR‐T setting.
Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatment
Severson, Kevin J. , Henderson, Nicholas , Ortolan, Luana dos Santos , Bellizzi, Andrew M. , Liu, Vincent , Link, Brian K. , Mangold, Aaron R. , Jabbari, Ali , Borcherding, Nicholas , Severson, Kevin J , Ortolan, Luana S , Rosenthal, Allison C, Bellizzi, Andrew M , Liu, Vincent , Link, Brian K , Jabbari, Ali , Mangold, A R , Borcherding, Nicholas , Henderson, Nicholas, Rosenthal, Allison

Mayo Clinic

Blood Advances | April 7, 2022 | Volume: 7 | Issue: 3 | Pages: 321-335

10.1182/bloodadvances.2021005991 | PMID 35390145 Get It

AbstractCutaneous T-cell lymphomas (CTCLs) are a spectrum of diseases with varied clinical courses caused by malignant clonal proliferation of skin-tropic T cells. Most patients have an indolent disease course managed with skin-directed therapies. In contrast, others, especially in advanced stages of disease or with specific forms, have aggressive progression and poor median survival. Sézary syndrome (SS), a leukemic variant of CTCL, lacks highly consistent phenotypic and genetic markers that may be leveraged to prevent the delay in diagnosis experienced by most patients with CTCL and could be useful for optimal treatment selection. Using single-cell mRNA and T-cell receptor sequencing of peripheral blood immune cells in SS, we extensively mapped the transcriptomic variations of nearly 50 000 T cells of both malignant and nonmalignant origins. We identified potential diverging SS cell populations, including quiescent and proliferative populations shared across multiple patients. In particular, the expression of AIRE was the most highly upregulated gene in our analysis, and AIRE protein expression could be observed over a variety of CTCLs. Furthermore, within a single patient, we were able to characterize differences in cell populations by comparing malignant T cells over the course of treatment with histone deacetylase inhibition and photopheresis. New cellular clusters after progression of the therapy notably exhibited increased expression of the transcriptional factor FOXP3, a master regulator of regulatory T-cell function, raising the potential implication of an evolving mechanism of immune evasion.
P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
Sonneveld, Pieter , Chanan‐Khan, A.A., Spicka, I, Munder, Markus , Mateos, MV, Mark, TM, Levin, M-D, Ahmadi, T., Qin, Xiang , Mayo, Wendy Garvin, Gai, X, Carey, Jodi, Carson, Robin, Spencer, Andrew , Weisel, Katja C , Nooka, Ajay K. , Masszi, Tamás , Beksaç, Meral , Spicka, I, Hungria, Vânia

Mayo Clinic

HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 12-12

10.1097/01.hs9.0000829588.31575.a9 Get It